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types of plaques, few studies have investigated the differ-
ent types of plaques by use of modern biochemical and
molecular biological techniques.
Previous studies by us, as well as by others,6,7 have
demonstrated increased levels of apoptosis and signaling
molecules of the apoptotic cascade in atherosclerotic
plaques as compared with normal arterial tissue.
Specifically, changes in the expression of the members of
the Bcl-2 family, p53, MDM2, CPP-32, and cyclin D1
have been reported.6-9 It has been proposed that apopto-
sis, especially of the smooth muscle cells (SMCs) in the
fibrous cap and the underlying media, weakens the plaque
structurally to the point of rupture whereas death of
macrophages and that of other cells contribute to the for-
mation of soft plaque cores and therefore make them vul-
nerable.10-12 However, the magnitude of apoptosis and
the signaling molecules involved in apoptosis in fibrous
versus atheromatous plaques have not been examined.
Plaque rupture may also be affected by the stability of
extracellular matrix (ECM). Remodeling of the arterial
In carotid atherosclerotic disease, fibrous and athero-
matous plaques have exhibited different levels of stabil-
ity.1-3 Fibrous plaque is made up of more than 70%
collagen-rich tissue that is thought to stabilize and prevent
rupture,4 whereas atheromatous plaques, characterized by
having high lipid content, thin fibrous cap, and abundant
macrophages, are known for their instability.5 Although
data support the clinical differences between these two
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Purpose: Atherosclerotic plaque instability may be a contributing factor to plaque complications, such as rupture,
thrombosis, and embolization. Of the two types of plaques, atheromatous and fibrous, the atheromatous type has been
reported to be vulnerable and unstable. This instability may be related to changes in the cell cycle and extracellular
matrix degradation. Apoptosis may weaken the plaque structurally. In addition, alteration of the cellular component
may lead to imbalances in associated proteolytic activity. Our study was designed to compare the two types of plaques
in terms of apoptosis, apoptosis-inducing factors, namely Fas/CD95/APO-1 and CPP-32/YAMA/caspase-3, and pro-
teolytic activity.
Methods: Carotid artery plaques were obtained from patients undergoing endarterectomy and were classified as either
atheromatous or fibrous on the basis of established criteria. Histologic study included hematoxylin and eosin staining,
Verhoeff’s van Gieson elastin staining, and trichrome staining. Detection of apoptosis was performed with the TUNEL
assay. Immunohistochemical studies were performed to localize the expression of CPP-32/YAMA and Fas/CD95.
Gelatin gel zymography was used to compare proteolytic activity levels in the two types of plaque.
Results: Apoptosis was significantly higher (P < .001) in atheromatous plaques (4.90% ± 1.27% [SEM]) as compared
with fibrous plaques (0.86% ± 0.46% [SEM]). Zymography demonstrated elevated levels of proteinases in atheroma-
tous plaques. Immunohistochemistry revealed significant increases in the expression of Fas/CD95 (P < .04) and CPP-
32/YAMA (P < .001) in atheromatous plaques as compared with that in fibrous plaques.
Conclusions: This is the first study comparing molecular factors that render atheromatous plaques more susceptible to
rupture than fibrous plaques. The higher number of apoptotic cells seen in atheromatous plaques as compared with
fibrous plaques could contribute to their greater instability. Immunoreactivity to cytoplasmic death domain, Fas/CD95
and CPP-32/YAMA, a prominent mediator of apoptosis, was consistent with the numbers of apoptotic cells detected.
The increased levels of proteolytic activity in atheromatous plaques may make these plaques more prone to rupture.
These data identifying some of the molecular events and biochemical pathways associated with plaque vulnerability may
help in the development of new strategies to prevent plaque rupture. (J Vasc Surg 2001;33:614-20.)
ECM13 occurs during all phases of human atherosclerosis
and is a process regulated at the levels of both synthesis and
degradation of matrix components. The macrophages and
T-cells associated with chronic inflammation are known to
secrete cytokines that can stimulate the production of met-
alloproteinases in the neighboring SMCs and endothelial
cells. Elevated levels of proteolytic activity can cause 
an increase in ECM degradation and affect plaque stabil-
ity.14-20 However, there is no report comparing proteolytic
activity in vulnerable atheromatous plaques and stable
fibrous plaques.
This study was performed to determine potential fac-
tors that may predispose atheromatous and fibrous
plaques to rupture. Degree of apoptosis, along with the
levels of known inducers of apoptosis, Fas/CD95/APO-1
and CPP-32/YAMA/caspase-3, were compared between
the two types of plaque. Proteolytic activity was examined
in fibrous and atheromatous plaques with the goal of
observing differences that may explain varying plaque sta-
bility between fibrous and atheromatous plaques.
MATERIALS AND METHODS
Patients. Two hundred consecutive patients, admit-
ted for primary carotid endarterectomy to the vascular
surgery division of Maimonides Medical Center between
April 1998 and February 1999 were considered for this
study. Institutional Review Board approval was obtained
for procurement of specimens, and all patients gave
informed written consent for the study. These carotid
endarterectomy specimens were stained by hematoxylin
and eosin and screened for type of plaque by an anatomic
pathologist (L.Z.) blinded to the clinical symptoms and
identity of each patient. Only five of the specimens were
found to be fibrous, whereas the rest were atheromatous
by standard criteria.17,20 The definition of fibrous plaque
was a complete lack of histologically identifiable atheroma
(macrophages and cholesterol). These plaques were made
up of only fibrous tissue. The five fibrous plaques and
eight randomly selected atheromatous plaques were cho-
sen for the study.
Preoperative imaging. All patients underwent preop-
erative carotid artery duplex ultrasound scanning. Carotid
artery duplex scanning was performed by registered vascular
technologists at a laboratory accredited by the Intersocietal
Commission for the Accreditation of Vascular Laboratories,
as part of the preoperative evaluation of these patients. The
common carotid, internal carotid, and external carotid arter-
ies were scanned bilaterally for the presence of occlusion or
stenosis.21-23 The arteries were scanned in transverse and
longitudinal sections with B-mode and color-flow imaging.
Local percent stenosis was estimated as a 10% interval, that
is, 60% to 70%. This interval reading accounted for mea-
surement error and variability.24 Velocity criteria were used
to confirm these data. The University of Washington crite-
rion was used to corroborate stenosis > 50% with a peak sys-
tolic velocity more than 125 cm/s.21 An end-diastolic
velocity of 100 cm/s25, 26 was used to corroborate severe
stenosis > 70%. All patients who underwent carotid
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endarterectomy had > 60% stenosis. None of the lesions
were identified as ulcerated or inhomogeneous by duplex
scanning.
Tissue specimens. Carotid artery plaques were
obtained immediately after endarterectomy. All operations
were performed with standard surgical techniques and min-
imal manipulation of the specimen. One half of each speci-
men was fixed in paraformaldehyde and embedded in
paraffin, whereas the remainder was snap-frozen immedi-
ately in liquid nitrogen and stored at –70°C until extraction.
Histologic study. Paraffin-embedded tissues were
sectioned transversely at 5-µm thickness and mounted on
3-aminopropyltriethoxysilane–coated slides. Five random
sections from each specimen were used for analysis. In
addition to routine hematoxylin and eosin staining used to
select specimens for the study, Gomori’s one-step
trichrome staining was performed to differentiate between
collagen and smooth muscle fibers, and Verhoeff ’s van
Gieson elastic tissue staining was performed to observe the
elastin network in the specimens.
DNA in situ end-labeling. Detection of apoptosis in
the carotid artery plaques was performed with terminal
deoxynucleotidyl transferase (TdT)–mediated digoxigenin-
deoxyuridinetriphosphate (dUTP) nick end-labeling of
free 3´ OH DNA termini of fragmented DNA present in
the apoptotic cells (TUNEL), with the ApopTag kit
(Intergen, Purchase, NY) as previously described.29 The
tissue sections were deparaffinized, rehydrated, and incu-
bated in 3% citric acid to remove calcium vesicles. Nuclei
were stripped of proteins by incubation with 20 µg/mL
proteinase K (Oncor, Gaitherburg, Md) for 15 minutes at
45°C. After equilibration in buffer for 5 minutes, sections
were covered with reaction buffer containing TdT enzyme
and digoxigenin-dUTP and incubated in humidifying
chambers for 1 hour at 37°C. One negative control 
slide (per batch) was incubated in the absence of TdT
enzyme. Positive control used was tumor tissue. After end-
labeling, the slides were immersed in stop-wash buffer for
20 minutes at 37°C. Blocking solution containing anti-
digoxigenin antibody (sheep polyclonal) conjugated to flu-
orescein was applied on tissue and incubated for 30 minutes
at 37°C in humidifying chambers. The antibody solution
was washed away with three changes of phosphate-buffered
saline solution for 5 minutes each. End-labeling was visu-
alized after counterstaining with propidium iodide and
observing the fluorescence under a Zeiss Axiophot fluo-
rescence microscope (Carl Zeiss, Inc, Thornwood, NY).
Immunohistochemistry. The primary antibodies
used in this study were mouse monoclonal antibodies for
CPP-32 and Fas (DAKO, Carpenteria, Calif). Formalin-
fixed paraffin-embedded tissue sections were deparaf-
finized and rehydrated. Antigen retrieval was performed by
heat treatment at 95°C with 0.01 mol/L citrate buffer, pH
6.0. After the endogenous peroxidase activity was
quenched with 0.3% hydrogen peroxide, the tissue sections
were incubated with primary antibodies CPP-32 at 1:200
dilution and Fas at a dilution of 1:200 for 1 hour at room
temperature. Sections were incubated with biotinylated
secondary antibody for 30 minutes at room temperature.
The bound primary antibodies were detected with the
LSAB2-HorseRadishPeroxidase detection system (DAKO).
The peroxidase reaction was developed with diaminoben-
zidine tetrachloride to produce a brown color at sites of
immunoreactivity. Subsequently, the slides were counter-
stained with Mayers’ hematoxylin for 1.5 minutes. Tumor
tissue was used as a positive control. The primary antibody
was omitted and substituted with an unrelated antibody at
the same dilution to check the specificity of the immuno-
histochemical reactions.
Quantification. Cells only positively stained by
TUNEL and containing apoptotic bodies were referred to
as “apoptotic cells.” Thus, multiple criteria were used to
identify apoptotic cells: TUNEL staining and morpho-
logic markings including chromatin condensation. Cells
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with these features have been confirmed to be apoptotic
with electron microscopic analysis in previous studies by
us28 and by others.29 The number of apoptotic cells per
thousand cells were counted manually at high-power mag-
nification (×1000) for each specimen (random fields were
selected). The apoptotic index was calculated as the num-
ber of apoptotic cells divided by the total number of cells
times 100. Cells positive for Fas and CPP-32 were counted
manually at original magnification × 400. Cells with no
nuclear staining, positive nuclear staining, and cytoplasmic
staining were quantified in six random fields per section.
Five sections per specimen were analyzed. The number of
positive cells is presented as a percentage of the total.
Protein extraction and estimation. Tissue samples
were minced and homogenized in salt buffer (50 mmol/L
Tris HCl pH 7.5; 2 mol/L NaCl; 0.02% Na Azide). After
centrifugation, the supernatants were dialyzed against
0.05 mol/L Tris HCl pH 7.9 overnight at 4°C. Total pro-
tein in the dialysate was determined by use of the Pierce
protein microassay kit (Pierce Chemical Co, Rockford, Ill)
as per the manufacturer’s instructions.
Zymography. Proteolytic activity in the extracts was
identified by use of substrate gels containing gelatin.
Extracts with equalized amounts of protein were mixed in
sample buffer in 1:2 ratio and 30 µL loaded on 10% poly-
acrylamide gels impregnated with gelatin (1 mg/mL)
(BioRad, Hercules, Calif). Electrophoresis was performed
under nonreducing conditions and at a constant voltage of
100 V. The gels were renatured for 30 minutes at room
temperature and developed overnight in a 37°C water
bath. The zymograms were stained in 0.5% (wt/vol)
Coomassie blue for 20 minutes. Destaining was per-
formed in 40% methanol and 10% acetic acid in distilled
water until gelatinolytic activity was seen as clear bands
against a background of stained gelatin. Polyacrylamide
gel electrophoresis under reducing conditions was used to
evaluate protein content.
Statistical analysis. The clinical data, risk factors, and
histologic and immunohistochemical findings were ana-
lyzed with the Student t test and χ2. The Fisher exact test
was used to compare the results obtained in the different
groups. Statistical analyses were performed with. Winks
4.21 program (Texasoft, Cedar Hill, Tex) and Instat 2.05a
programs (Graphad, San Diego, Calif). 
RESULTS
Patient demographics
There were seven men and six women with ages rang-
ing from 63 to 85 years (mean, 73.6 ± 1.9 years). Eight of
the patients had symptoms (history of stroke, transient
ischemic attack, or amaurosis fugax), whereas five were
symptom free. Patient demographics, risk factors, and
clinical symptoms are given in Table I. None of the
women were receiving hormone replacement therapy.
Histologic study
Fibrous plaques were observed to contain more smooth
Fig 1. Apoptosis in fibrous and atheromatous plaque. Yellow-
green fluorescence represents TUNEL-positive apoptotic bodies
against red background of propidium iodide counterstained
nuclei of nonapoptotic cells. (Original magnification ×1000.)
Fig 2. Apoptosis in fibrous and atheromatous plaque.
Differences in incidence of apoptosis between fibrous and athero-
matous plaque. Cumulative data of all atheromatous and fibrous
plaques were obtained. Number of apoptotic cells per thousand
cells were counted manually at high-power magnification (origi-
nal magnification ×1000) for each specimen (random fields were
selected).
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muscle cells (identified with anti-alpha actin staining and
morphologic study) than atheromatous plaques. Verhoeff’s
elastin staining and trichrome staining also showed a more
developed extracellular matrix in atheromatous plaques
than in fibrous plaques. The histopathologic findings in the
patient groups are summarized in Table II.
Apoptosis detection
We observed that most of TUNEL-positive cells occur
within the inflammatory regions of atheromatous plaques,
composed mostly of macrophages, smaller number of T
lymphocytes, and few B lymphocytes (data not shown).
The atheromatous plaques contained 4.9% ± 1.27%
TUNEL-positive apoptotic cells as compared with 0.86% ±
0.46% cells in the fibrous plaques (P < .001). In the athero-
matous plaques, TUNEL-positive cells were most predom-
inant in the lipid core, followed by the fibrous cap and the
plaque shoulder region. There were fewer apoptotic cells in
the medial layers. On the other hand, fibrous plaque
demonstrated an even or scattered distribution of the less
than 1% TUNEL-positive cells (Figs 1 and 2). The apop-
totic index in the symptomatic group was 3.26, and that in
the asymptomatic group was 3.45 (P = .47). There was no
correlation of apoptosis with the degree of stenosis.
Immunohistochemical localization of the expression of
mediators of apoptosis
CPP-32/YAMA. Cells expressing CPP-32 were
preferentially located in areas of atheromatous plaques
that had increased evidence of apoptosis, namely lipid
core, fibrous cap, and shoulder region. In the atheroma-
tous plaque, 20.3% ± 1.78% of the cells were CPP-32 pos-
itive, whereas in the fibrous plaque, significantly fewer
cells were positive (11.7%; P < .001) (Fig 3).
Fas. There were 17.5% ± 2.35% of positive cells in the
atheromatous plaques and no reactivity in the fibrous
plaques (P < .04). This correlated with the apopotic cell
death observed in serial sections of these specimens (Fig
3). We could quantify the immunoreactivity to this
inducer of apoptosis, although the specimens demon-
strated weakly positive staining results.
Zymography. Zymograms with extracts used from
carotid artery plaque specimens demonstrated proteolytic
activity. However, there was increased gelatinolytic activity
in the atheromatous plaques as compared with the fibrous
samples. The activities ranged from 68-94 kDa (Fig 4);
however, the band intensities were not quantified.
Clinicopathologic correlation
With the risk factors analyzed, diabetes mellitus,
hypertension, and smoking (Table I), no correlation could
be established between plaque type and clinical symptoms.
Patients who had quit smoking were considered as positive
for tobacco use.
DISCUSSION
The data from this study suggest significant differ-
ences in the apoptotic cascade in between atheromatous
and fibrous carotid artery plaques. We have observed
greater numbers of apoptotic cells in atheromatous
plaques as compared with fibrous plaques. Programmed
cell death in the atheromatous plaques was mainly found
Table I. Clinical risk factors
Atheromatous (n = 8) Fibrous (n = 5)
Asymptomatic (n = 3) Symptomatic (n = 5) Asymptomatic (n = 3) Symptomatic (n = 2) P value
Age ± SEM (y) 72.7 ± 2.9 73.2 ± 3.6 69.7 ± 3.2 82 ± 2 NS
Male/female (7:6) 2:1 3:2 1:2 2:0 0.67
Diabetes mellitus (n = 4) 0 2 2 0 0.56
Hypertension (n = 5) 1 3 0 1 0.44
Tobacco (n = 7) 0 4 1 2 0.6
P values compare atheromatous with fibrous plaque.
Table II. Histopathogic findings
Atheromatous (n = 8) Fibrous (n = 5)
Asymptomatic (n = 3) Symptomatic (n = 5) Asymptomatic (n = 3) Symptomatic (n = 2)
Plaque rupture 1 2 — —
Cap thinning 2 2 — —
Plaque necrosis 1 2 — —
Cap foam cells 2 1 — —
Macrophages 2 4 — —
Intraplaque fibrin — 1 — —
Intraplaque hemorrhage 3 3 1 —
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within regions of inflammatory cell infiltration. In con-
trast, apoptotic cells in fibrous plaques were distributed
throughout the whole plaque. Therefore, they may not be
able to undermine or compromise plaque stability.6,7 In
addition, programmed cell death of SMCs may lead to
imbalances in secretion of proteases associated with
them,29 whereas cell debris of dead macrophages and
other cells may contribute to gruel formation. It has been
suggested that the death of SMCs can be detrimental for
plaque stability because most of the interstitial collagen
fibers that are important for the tensile strength of the
fibrous cap are produced by SMCs.30 Because SMCs and
macrophages have been characterized as the key cell types
involved with matrix turnover, a high degree of apoptosis
in atheromatous plaques may account for their relative
instability when compared with fibrous plaques.
The apoptosis observed by TUNEL assay identifies
DNA fragmentation that occurs at the final phase of the
apoptotic cascade. Kockx and Herman30 found that dur-
ing TUNEL assay if aspecific labeling is avoided, as in this
study, the percentage of apoptosis was low in atheroma-
tous plaques. The half-life of apoptotic cells is only a few
hours. Even a low incidence of apoptosis has great cell
kinetic significance because the short duration of the
apoptotic process makes it histologically inconspicuous.
Previous reports have emphasized that a small proportion
of apoptotic cells visualized in tissue sections can represent
a considerable magnitude of cell loss.7,11,31
Cysteine protease CPP-32/YAMA is an inducer for
mammalian programmed cell death and is an early marker
of apoptosis.32 Our data demonstrate decreased immuno-
positivity for CPP-32 in fibrous plaques. The fact that cells
expressing CPP-32 are preferentially present in the lipid
core, fibrous cap, and shoulder regions lends credence to
the finding of a significant number of apoptotic cells in
these regions. CPP-32 has been shown to lead to apopto-
sis by cleaving and deactivating poly (ADP-ribose) poly-
merase, an enzyme required for DNA repair and genome
integrity.32 Recent studies have demonstrated the expres-
sion of CPP-32 in apoptotic cells of carotid artery
plaques.9 Our data not only corroborate these findings
but also show differential expression of CPP-32 in the two
types of plaques studied.
Fas is a cellular death domain protein that is activated
by Fas ligand in the apoptotic pathway.33,34 The positive
expression of Fas/CD95 in atheromatous plaques, as
compared with its negative immunoreactivity in fibrous
plaques, was consistent with the greater numbers of apop-
totic cells observed in these plaques. Because fibrous
plaques demonstrated no detectable immunopositivity for
Fas, even after repeated immunohistochemical staining, it
is possible that cells in the fibrous plaques do not go
through the same apoptotic pathway as those in athero-
matous plaques. In the atheromatous plaques, Fas seemed
to colocalize with inflammatory cells in the necrotic core.
Scant expression of Fas may be expected because these
cells are either absent or present in small numbers in
fibrous plaques.
Atherosclerotic plaque stability also may depend on the
structural integrity of its extracellular matrix skeleton. We
observed increased proteolytic activity in atheromatous
plaque as compared with fibrous plaques. Reduction of
ECM, compromising plaque stability, may result from
either decreased synthesis of ECM by SMCs or its
Fig 3. A, Immunohistochemical localization of CPP-32 in
atheromatous plaques. Note positive staining (brown) for CPP-
32. (Original magnification ×400.) B, Immunohistochemical
localization of Fas in atheromatous plaques. Note positive stain-
ing result (brown) for Fas. (Original magnification ×400.) 
C, Negative control. (Original magnification ×400.)
A
B
C
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characteristics of the plaque in response to hemody-
namic forces, or a combination of factors may play a sig-
nificant role.
The pathogenesis of intraplaque events in atheroscle-
rotic carotid artery plaques remains a matter of debate.
Our data indicate that plaque instability may be caused by
programmed cell death of SMCs and inflammatory cells
along with ECM degradation. The clear differences in the
degree of apoptosis, level of expression of mediators of
apoptosis and proteolytic activity between the two groups
may be correlated with plaque vulnerability. The challenge
remains to further elucidate molecular events and the
mechanisms involved to develop future modalities for pre-
vention of plaque rupture.
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